Emerging infectious disease in the 21st century

Current Opinion in Infectious Diseases

Volumn 13, Issue 3, 2000, Pages 265-275

  Pollard, Andrew J ^a,b   Dobson, Simon R ^a  

^a BC CHILDREN S HOSPITAL   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; CEPHALOSPORIN; CHLOROQUINE; DALFOPRISTIN PLUS QUINUPRISTIN; LINEZOLID; MEFLOQUINE; MENINGITIS VACCINE; OSELTAMIVIR; PLECONARIL; PNEUMOCOCCUS VACCINE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VANCOMYCIN; ZANAMIVIR;

DENGUE; EHRLICHIOSIS; ENCEPHALITIS; ENTEROVIRUS INFECTION; HANTAVIRUS PULMONARY SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INFECTION; INFLUENZA; LEISHMANIASIS; LYME DISEASE; MALARIA; MENINGITIS; PLAGUE; PNEUMONIA; PRION DISEASE; REVIEW; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; TUBERCULOSIS; VIRUS HEMORRHAGIC FEVER;

EID: 0034118710     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200006000-00011     Document Type: Review

References (134)

1. 1 World Health Organization. Removing obstacles to healthy development. Switzerland: Atar; 1999. This is a recent view of the state of the world's health that outlines the important areas for target by the World Health Organization in the year 2000 and beyond. This information is also available via the World Health Organization website (http:// www.WHO.int/).
2. 2 Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis 1995; 1:7-15.
3. 3 Lopez N, Padula P, Rossi C, Lazaro ME, Franze-Fernandez MT. Genetic identification of a new hantavirus causing severe pulmonary syndrome in Argentina. Virology 1996; 220:223-226.
4. 4 Billoir F, Attoui H, Simon S, Gallian P, de Micco P, de Lamballerie X. Molecular diagnosis of group B coltiviruses infections. J Virol Methods 1999; 81:39-45.
5. 5 Regnery RL, Olson JG, Perkins BA, Bibb W. Serological response to 'Rochalimaea henselae' antigen in suspected cat-scratch disease. Lancet 1992; 339:1443-1445.
6. 6 Welch DF, Pickett DA, Slater LN, Steigerwalt AG, Brenner DJ. Rochalimaea henselae sp. nov., a cause of septicemia, bacillary angiomatosis, and parenchymal bacillary peliosis. J Clin Microbiol 1992; 30:275-280.
7. 7 Morzunov SP, Feldmann H, Spiropoulou CF, Semenova VA, Rollin PE, Ksiazek TG, et al. A newly recognized virus associated with a fatal case of hantavirus pulmonary syndrome in Louisiana. J Virol 1995; 69:1980-1983.
8. 8 Hoge CW, Shlim DR, Echeverria P. Cyanobacterium-like cyclospora species. N Engl J Med 1993; 329:1504-1505.
9. 9 Walker DH. Tick-transmitted infectious diseases in the United States. Annu Rev Public Health 1998; 19:237-269. A thorough review of important tick-borne disease in North America is presented.
10. 10 Chen SM, Dumler JS, Bakken JS, Walker DH. Identification of a granulocytotropic Ehrlichia species as the etiologic agent of human disease. J Clin Microbiol 1994; 32:589-595.
11. 11 Bakken JS, Dumler JS, Chen SM, Eckman MR, Van Etta LL, Walker DH. Human granulocytic ehrlichiosis in the upper Midwest United States. A new species emerging? JAMA 1994; 272:212-218.
12. 12 Schaffner W, Standaert SM. Ehrlichiosis: in pursuit of an emerging infection. N Engl J Med 1996; 334:262-263.
13. 13 McCormack JG, Allworth AM, Selvey LA, Selleck PW. Transmissibility from horses to humans of a novel paramyxovirus, equine morbillivirus (EMV). J Infect 1999; 38:22-23.
14. 14 Zaki AM. Isolation of a flavivirus related to the tick-borne encephalitis complex from human cases in Saudi Arabia. Trans R Soc Trop Med Hyg 1997; 91:179-181.
15. 15 Salas R, de Manzione N, Tesh RB, Rico-Hesse R, Shope RE, Betancourt A, et al. Venezuelan haemorrhagic fever. Lancet 1991; 338:1033-1036.
16. 16 Selvey LA, Wells RM, McCormack JG, Ansford AJ, Murray K, Rogers RJ, et al. Infection of humans and horses by a newly described morbillivirus. Med J Aust 1995; 182:642-645.
17. 17 Alter HJ, Nakatsuji Y, Melpolder J, Wages J, Wesley R, Shih JW, et al. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med 1997; 336:747-754.
18. 18 Nkengasong JN, Janssens W, Heyndrickx L, Fransen K, Ndumbe PM, Motte J, et al. Genotypic subtypes of HIV-1 in Cameroon. AIDS 1994; 8:1405-1412.
19. 19 Claas EC, de Jong JC, van Beek R, Rimmelzwaan GF, Osterhaus AD. Human influenza virus A/HongKong/156/97 (H5N1) infection. Vaccine 1998; 16:977-978.
20. 20 Peiris M, Yuen KY, Leung CW, Chan KH, Ip PL, Lai RW, et al. Human infection with influenza H9N2. Lancet 1999; 354:916-917.
21. 21 Johnson AM, de Souza LT, Ferreira IB, Pereira LE, Ksiazek TG, Rollin PE, et al. Genetic investigation of novel hantaviruses causing fatal HPS in Brazil. J Med Virol 1999; 59:527-535.
22. 22 Johnson AM, Bowen MD, Ksiazek TG, Williams RJ, Bryan RT, Mills JN, et al. Laguna Negra virus associated with HPS in western Paraguay and Bolivia. Virology 1997; 238:115-127.
23. 23 Levis S, Morzunov SP, Rowe JE, Enria D, Pini N, Calderon G, et al. Genetic diversity and epidemiology of hantaviruses in Argentina. J Infect Dis 1998; 177:529-538.
24. 24 Hjelle B, Lee SW, Song W, Torrez-Martinez N, Song JW, Yanagihara R, et al. Molecular linkage of hantavirus pulmonary syndrome to the white-footed mouse, Peromyscus leucopus: genetic characterization of the M genome of New York virus. J Virol 1995; 69:8137-8141.
25. 25 Lee KE, Umapathi T, Tan CB, Tjia HT, Chua TS, Oh HM, et al. The neurological manifestations of Nipah virus encephalitis, a novel paramyxovirus. Ann Neurol 1999; 46:428-432.
26. 26 Grohmann GS, Glass RI, Pereira HG, Monroe SS, Hightower AW, Weber R, et al. Enteric viruses and diarrhea in HIV-infected patients. Enteric Opportunistic Infections Working Group. N Engl J Med 1993; 329:14-20.
27. 27 Prusiner SB. Prions. Proc Natl Acad Sci USA 1998; 95:13363-13383. A superb review of prions and prion diseases is presented.
28. 28 Gentsch JR, Das BK, Jiang B, Bhan MK, Glass RI. Similarity of the VP4 protein of human rotavirus strain 118E to that of the bovine B223 strain. Virology 1993; 194:424-430.
29. 29 Lisieux T, Coimbra M, Nassar ES, Burartini MN, de Souza LT, Ferreira I, et al. New arenavirus isolated in Brazil. Lancet 1994; 343:391-392.
30. 30 Duchin JS, Koster FT, Peters CJ, Simpson GL, Tempest B, Zaki SR, et al. Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. The Hantavirus Study Group. N Engl J Med 1994; 330:949-955.
31. 31 Koopmans MP, Goosen ES, Lima AA, McAuliffe IT, Nataro JP, Barrett LJ, et al. Association of torovirus with acute and persistent diarrhea in children, Pediatr Infect Dis J 1997; 18:504-507.
32. 32 Krishnan T, Naik TN. Electronmicroscopic evidence of torovirus like particles in children with diarrhoea. Indian J Med Res 1997; 105:108-110.
33. 33 Higa N, Honma Y, Albert MJ, Iwanaga M. Characterization of Vibrio cholerae O139 synonym Bengal isolated from patients with cholera-like disease in Bangladesh. Microbiol Immunol 1993; 37:971-974.
34. 34 Rwaguma EB, Lutwama JJ, Sempala SD, Kiwanuka N, Kamugisha J, Okware S, et al. Emergence of epidemic O'nyong-nyong fever in southwestern Uganda, after an absence of 35 years. Emerg Infect Dis 1997; 3:77. [Letter]
35. 35 Lundstrum JO. Mosquito-borne viruses in western Europe: a review. J Vector Ecol 1999; 24:1-39. This is a good review of diseases spread by mosquitoes in Europe.
36. 36 Smithburn KC, Hughes TP, Burke AW, Paul JH. A neurotropic virus isolated from the blood of a native of Uganda. Am J Trop Med Hyg 1940; 20:471-492.
37. 37 Hubalek Z, Halouzka J. West Nile fever: a reemerging mosquito-borne viral disease in Europe. Emerg Infect Dis 1999; 5:643-650. This is the best review on WNV in Europe.
38. 38 Calisher CH. Medically important arboviruses of the United States and Canada. Clin Microbiol Rev 1994; 7:89-116.
39. 39 Savage HM, Ceianu C, Nicolescu G, Karabatsos N, Lanciotti R, Vladimirescu A, et al. Entomologic and avian investigations of an epidemic of West Nile fever in Romania in 1996, with serologic and molecular characterization of a virus isolate from mosquitoes. Am J Trop Med Hyg 1999; 61:600-611.
40. 40 Tsai TF, Popovici F, Cernescu C, Campbell GL, Nedelcu NI. West Nile encephalitis epidemic in southeastern Romania. Lancet 1998; 352:767-771.
41. 41 Anon. Outbreak of West Nile-like viral encephalitis: New York, 1999. MMWR Morb Mortal Wkly Rep 1999; 46:845-849. Although limited information is presented, this is a useful description of the outbreak. Several other MMWR reports in 1999 and 2000, with this one, complete the picture of this outbreak and the public health response.
42. 42 Anderson JF, Andreadis TG, Vossbrinck CR, Tirrell S, Wakem EM, French RA, et al. Isolation of West Nile virus from mosquitoes, crows, and a Cooper's hawk in Connecticut. Science 1999; 286:2331-2333. See [43*].
43. 43 Lanciotti RS, Roehrig JT, Deubel V, Smith J, Parker M, Steele K, et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 1999; 286:2333-2337. This paper and [42*] track the origin of the virus.
44. 44 Trent DW, Monath TP, Bowen GS, Vorndam AV, Cropp CB, Kemp GE. Variation among strains of St. Louis encephalitis virus: basis for a genetic, pathogenetic, and epidemiologic classification. Ann NY Acad Sci 1980; 354:219-237.
45. 45 Chandler LJ, Nordoff NG. Identification of genetic variation among St. Louis encephalitis virus isolates, using single-strand conformation polymorphism analysis. J Virol Methods 1999; 80:169-178.
46. 46 Gratz NG. Emerging and resurging vector-borne diseases. Annu Rev Entomol 1999; 44:51-75. This is an excellent review of vector-borne diseases
47. 47 Kouri G, Guzman MG, Bravo J. Hemorrhagle dengue in Cuba: history of an epidemic. Bull Pan Am Health Organ 1986; 20:24-30.
48. 48 Anon, Dengue fever at the U.S.-Mexico border, 1995-1996. MMWR Morb Mortal Wkly Rep 1996; 45:841-844.
49. 49 Centers for Disease Control and Prevention. Dengue fever at the US-Mexico border, 1995-1996. JAMA 1996; 276:1464-1465.
50. 50 Hinman A. Eradication of vaccine-preventable diseases. Annu Rev Public Health 1999; 20:211-229.
51. 51 Sawyer MH. Enterovirus infections: diagnosis and treatment. Pediatr Infect Die J 1999; 18(12):1033-1039; quiz 1040. This is a good review of current issues in management of enteroviral illnesses.
52. 52 Kearns GL, Abdel-Rahman SM, James LP, Blowey DL, Marshall JD, Wells TG, et al. Single-dose pharmacokinetics of a pteconaril (VP63843) oral solution in children and adolescents. Pediatric Pharmacology Research Unit Network. Antimicrob Agents Chemother 1999; 43:634-638.
53. 53 Pevear DC, Tull TM, Seipel ME, Groarke JM. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother 1999; 43:2109-2115. This paper presents important data for management of patients, showing broad activity of the drug against enterovirus isolates.
54. 54 Schiff GM, Sherwood JR. Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection. J Infect Dis 2000; 181:20-26. Evidence is provided that pleconaril works in experimental infection.
55. 55 Schmugge M, Lauener R, Seger RA, Gungor T, Bossart W. Chronic enteroviral meningo-encephalitis in X-linked agammaglobulinaemia: favourable response to anti-enteroviral treatment. Eur J Pediatr 1999; 158:1010-1011.
56. 56 Shafran SD, Halota W, Gilbert D, Bernstein J, Meislin H, Reiss M, et al. Pleconaril is effective for enteroviral meningitis in adolescents and adults: a randomized placebo-controlled multicenter trial. Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco: American Society for Microbiology; 1999:435. This paper provides preliminary data on use of pleconaril in a useful clinical setting. The full publication is eagerly awaited.
57. 57 Dolin R. Enterovirus 71:emerging infections and emerging questions [editorial]. N Engl J Med 1999; 341:984-985. This editorial considers the EV71 outbreak in Taiwan.
58. 58 Landry ML, Fonseca SN, Cohen S, Bogue CW. Fatal enterovirus type 71 infection: rapid detection and diagnostic pitfalls. Pediatr Infect Dis J 1995; 14:1095-1100.
59. 59 AbuBakar S, Chee HY, Al-Kobaisi MF, Xiaoshan J, Chua KB, Lam SK. Identification of enterovirus 71 isolates from an outbreak of hand, foot and mouth disease (HFMD) with fatal cases of encephalomyelitis in Malaysia. Virus Res 1999; 61:1-9.
60. 60 Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999; 341:929-935. Data are presented on cases of EV71 during the Taiwan epidemic.
61. 61 Chang LY, Lin TY, Hsu KH, Huang YC, Lin KL, Hsueh C, et al. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 1999; 354:1682-1686.
62. 62 Deibel R, Gross LL, Collins DN. Isolation of a new enterovirus (38506). Proc Soc Exp Biol Med 1975; 148:203-207.
63. 63 Cardosa MJ, Krishnan S, Tio PH, Perera D, Wong SC. Isolation of subgenus B adenovirus during a fatal outbreak of enterovirus 71-associated hand, foot, and mouth disease in Sibu, Sarawak. Lancet 1999; 354:987-991.
64. 64 Brown BA, Oberste MS, Alexander Jr JP, Kennett ML, Pallansch MA. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol 1999; 73:9969-9975. Evidence is presented for the genetic diversity of EV71 isolates and their rapid evolution.
65. 65 Akasu Y. Outbreak of aseptic meningitis due to ECHO-9 in northern Kyushu island in the summer of 1997. Kurume Med J 1999; 46:97-104.
66. 66 Yoshida H, Hong Z, Yoneyama T, Yoshii K, Shimizu H, Ota K, et al. Phylogenic analysis of echovirus type 30 isolated from a large epidemic of aseptic meningitis in Japan during 1997-1998. Jpn J Infect Dis 1999; 52:160-163.
67. 67 Vieth UC, Kunzelmann M, Diedrich S, Timm H, Ammon A, Lyytikainen O, et al. An echovirus 30 outbreak with a high meningitis attack rate among children and household members at four day-care centers. Eur J Epidemiol 1999; 15:655-658.
68. 68 Chambon M, Bailly JL, Beguet A, Henquell C, Archimbaud C, Gaulme J, et al. An outbreak due to echovirus type 30 in a neonatal unit in France in 1997: usefulness of PCR diagnosis. J Hosp Infect 1999; 43:63-68.
69. 69 Schumacher JD, Chuard C, Renevey F, Matter L, Regamey C. Outbreak of echovirus 30 meningitis in Switzerland. Scand J Infect Dis 1999; 31:539-542.
70. 70 Handsher R, Shulman LM, Abramovitz B, Silberstein I, Neuman M, Tepperberg-Oikawa M, et al. A new variant of echovirus 4 associated with a large outbreak of aseptic meningitis. J Clin Virol 1999; 13:29-36.
71. 71 Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev 1992; 56:152-179.
72. 72 Rohm C, Zhou N, Suss J, Mackenzie J, Webster RG. Characterization of a novel influenza hemagglutinin, H15: criteria for determination of influenza A subtypes. Virology 1996; 217:508-516.
73. 73 Schmaljohn C, Hjelle B. Hantaviruses: a global disease problem. Emerg Infect Dis 1997; 3:96-104.
74. 74 Clement J, Heyman P, McKenna P, Colson P, Avsic-Zupanc T. The hantaviruses of Europe: from the bedside to the bench. Emerg Infect Dis 1997; 3:205-211.
75. 75 Rodriguez-Moran P, Kelly C, Williams TM, Hjelle B. Hantavirus infection in the Four Corners region of USA in 1998. Lancet 1998; 352:1353.
76. 76 Toro J, Vega JD, Khan AS, Mills JN, Padula P, Terry W, et al. An outbreak of hantavirus pulmonary syndrome, Chile, 1997. Emerg Infect Dis 1998; 4:687-694.
77. 77 Farrar JJ. Nipah-virus encephalitis: investigation of a new infection. Lancet 1999; 354:1222-1223. This paper provides a description of the outbreak of Nipah virus encephalitis.
78. 78 Paton NI, Leo YS, Zaki SR, Auchus AP, Lee KE, Ling AE, et al. Outbreak of Nipah-virus infection among abattoir workers in Singapore. Lancet 1999; 354:1253-1256.
79. 79 Chua KB, Goh KJ, Wong KT, Kamarulzaman A, Tan PS, Ksiazek TG, et al. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet 1999; 354:1257-1259.
80. 80 O'Sullivan JD, Allworth AM, Paterson DL, Snow TM, Boots R, Gleeson LJ, et al. Fatal encephalitis due to novel paramyxovirus transmitted from horses. Lancet 1997; 349:93-95.
81. 81 Khabbaz RF. Emerging viral infections. Adv Pediatr Infect Dis 1999; 14:1-27. This paper considers some emerging viral infections.
82. 82 Khan AS, Sanchez A, Pflieger AK. Filoviral haemorrhagic fevers. Br Med Bull 1998; 54:675-692. This is a good resource for recent information on Ebola and Marburg viruses.
83. 83 Baird JK, Hoffman SL. Prevention of malaria in travelers. Med Clin North Am 1999; 83:923-944.
84. 84 White NJ. Drug resistance in malaria. Br Med Bull 1998; 54:703-715. A review of drug resistance in malaria is provided.
85. 85 Whitby M. Drug resistant Plasmodium vivax malaria. J Antimicrob Chemother 1997; 40:749-752.
86. 86 Collins WE, Jeffery GM. Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg 1996; 55:243-249.
87. 87 Holder AA. Malaria vaccines. Proc Natl Acad Sci USA 1999; 96:1167-1169.
88. 88 Brown P, Bradley R. 1755 and all that: a historical primer of transmissible spongiform encephalopathy. Br Med J 1998; 317:1688-1692. This is a well-written review of the history of prion diseases.
89. 89 Will RG, Ironside JW, Zeidler M, Cousens SN, Eatibeiro K, Alperovitch A, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347:921-925.
90. 90 Johnson RT, Gibbs Jr CJ. Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N Engl J Med 1998; 339:1994-2004.
91. 91 Tan L, Williams MA, Khan MK, Champion HC, Nielsen NH. Risk of transmission of bovine spongiform encephalopathy to humans in the United States: report of the Council on Scientific Affairs. American Medical Association. JAMA 1999; 281:2330-2339.
92. 92 Forward KR. The epidemiology of penicillin resistance in Streptococcus pneumoniae. Semin Respir Infect 1999; 14:243-254.
93. 93 McDougal LK, Rasheed JK, Biddle JW, Tenover FC. Identification of multiple clones of extended-spectrum cephalosporin-resistant Streptococcus pneumoniae isolates in the United States. Antimicrob Agents Chemother 1995; 39:2282-2288.
94. 94 Crook DW, Spratt BG. Multiple antibiotic resistance in Streptococcus pneumoniae. Br Med Bull 1998; 54:595-610.
95. 95 Tomasz A. New faces of an old pathogen: emergence and spread of multidrug-resistant Streptococcus pneumoniae. Am J Med 1999; 107(Suppl 1A):55S-82S.
96. 96 Coffey TJ, Dowson CG, Daniels M, Spratt BG. Genetics and molecular biology of beta-lactam-resistant pneumococci. Microb Drug Resist 1995; 1:29-34.
97. 97 Klugman KP, Feldman C. Penicillin-and cephalosporin-resistant Streptococcus pneumoniae. Emerging treatment for an emerging problem. Drugs 1999; 58:1-4.
98. 98 Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19:187-195. This paper presents data from the study that launched the new pneumococcal conjugate vaccine, licensed by the US Food and Drug Administration in early 2000.
99. 99 Anon, Update: Staphylococcus aureus with reduced susceptibility to vancomycin: United States, 1997. MMWR Morb Mortal Wkly Rep 1997; 46:813-815. (Published erratum appears in MMWR Morb Mortal Wkly Rep 1997; 46:851.)
100. 100 Witte W. Antibiotic resistance in gram-positive bacteria: epidemiological aspects. J Antimicrob Chemother 1999; 44(Suppl A):1-9.
101. 101 O'Brien FG, Pearman JW, Gracey M, Riley TV, Grubb WB. Community strain of methicillin-resistant Staphylococcus aureus involved in a hospital outbreak. J Clin Microbiol 1999; 37:2858-2862.
102. 102 Harbarth S, Rutschmann O, Sudre P, Pittet D. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch Intern Med 1998; 158:182-189.
103. 103 Anon. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus: Minnesota and North Dakota, 1997-1999. Morb Mortal Wkly Rep 1999; 48:707-710.
104. 104 Rotun SS, McMath V, Schoonmaker DJ, Maupin PS, Tenover FC, Hill BC, et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999; 5:147-149.
105. 105 Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350:1670-1673.
106. 106 Kantzanou M, Tassios PT, Tseleni-Kotsovili A, Legakis NJ, Vatopoulos AC. Reduced susceptibility to vancomycin of nosocomial isolates of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1999; 43:729-731.
107. 107 Linden PK. Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance. Am J Med 1998; 104 (Suppl 5A):24S-33S.
108. 108 Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin Infect Dis 2000; 30:146-151.
109. 109 Goossens H. The epidemiology of vancomycin-resistant enterococci. Curr Opin Infect Dis 1999; 12:537-541.
110. 110 French GL. Enterococci and vancomycin resistance. Clin Infect Dis 1998; 27(Suppl 1):S75-S83.
111. 111 Murray BE. Vancomycin-resistant enterococci. Am J Med 1997; 102:284-293.
112. 112 Moellering Jr RC. The specter of glycopeptide resistance: current trends and future considerations. Am J Med 1998; 104 (Suppl 5A):3S-6S.
113. 113 Montecalvo MA, Jarvis WR, Uman J, Shay DK, Petrullo C, Rodney K, et al. Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting. Ann Intern Med 1999; 131:269-272.
114. 114 Salo WL, Aufderheide AC, Buikstra J, Holcomb TA. Identification of Mycobacterium tuberculosis DNA in a pre-Columbian Peruvian mummy. Proc Natl Acad Sci USA 1994; 91:2091-2094.
115. 115 Bloom BR, Murray CJ. Tuberculosis: commentary on a reemergent killer. Science 1992; 257:1055-1064.
116. 116 Bloom BR. Tuberculosis. Back to a frightening future. Nature 1992; 358:538-539.
117. 117 Bloch AB, Cauthen GM, Onorato IM, Dansbury KG, Kelly GD, Driver CR, et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 1994; 271:665-671.
118. 118 Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 1995; 8:496-514.
119. 119 Dennis DT. Plague in India. Br Med J 1994; 309:893-894.
120. 120 Deodhar NS, Yemul VL, Banerjee K. Plague that never was: a review of the alleged plague outbreaks in India in 1994. J Public Health Policy 1998; 19:184-199.
121. 121 Kotloff KL. Bacterial diarrheal pathogens. Adv Pediatr Infect Dis 1999; 14:219-267. A good review of pathogens that cause gastroenteritis is presented.
122. 122 Slutsker L, Altekruse SF, Swerdlow DL. Foodborne diseases. Emerging pathogens and trends. Infect Dis Clin North Am 1998; 12:199-216.
123. 123 Shapiro ED. Tick-borne diseases. Adv Pediatr Infect Dis 1997; 13:187-218.
124. 124 Shapiro ED. Lyme disease. Pediatr Rev 1998; 19:147-154.
125. 125 Lapeyssonnie L. La meningite cerebro-spinale en Afrique. Bull World Health Organ 1963; 28(Suppl 1):3-114.
126. 126 Achtman M. Microevolution and epidemic spread of serogroup A Neisseria meningitidis: a review. Gene 1997; 192:135-140.
127. 127 Peltola H. Emergency or routine vaccination against meningococcal disease in Africa? [editorial] Lancet 2000; 355:3. This is an editorial review of [128], which discusses approaches to management of epidemic meningococcal disease.
128. 126 Woods CW, Armstrong G, Sackey SO, Tetteh C, Bugri S, Parkins BA, et al. Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa. Lancet 2000; 355:30-33.
129. 129 Wilson N, Baker M, Martin D, Lennon D, O'Hallahan J, Jones N, et al. Meningococcal disease epidemiology and control in New Zealand. N Z Med J 1995; 108:437-442.
130. 130 Wang JF, Caugant DA, Morelli G, Koumare B, Achtman M. Antigenic and epidemiologic properties of the ET-37 complex of Neisseria meningitidis. J Infect Dis 1993; 167:1320-1329.
131. 131 Diermayer M, Hedberg K, Hoesly F, Fischer M, Perkins B, Reeves M, et al. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. JAMA 1999; 281:1493-1497.
132. 132 Pollard AJ, Levin M. Vaccines for prevention of meningococcal disease. Pediatr Infect Dis J. 2000; 19:333-45. The current state of available and experimental meningococcal vaccines in human trials is reviewed.
133. 133 Donaldson L, Moores Y, Howe J. Introduction of immunisation against group C meningococcal infection. Report no. PL/CMO/99/2. London: Department of Health; 1999.
134. 134 Maiden MC, Spratt BG. Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet 1999; 354:615-616.